<DOC>
	<DOCNO>NCT01215578</DOCNO>
	<brief_summary>The purpose study identify predictive molecular marker response continuous daily sunitinib dose 37.5 mg use patient poorly-differentiated Advanced/Inoperable NEURO-Endocrine Tumors . Hypothesis : - To distinguish molecular marker base expression initial biopsy , detection proteomic analysis demonstrate tumor vascular cell straightaway sensitive sunitinib ( marker sensitivity ) . - The presence marker initial biopsy predict sensitivity sunitinib ( Positive predictive value marker )</brief_summary>
	<brief_title>Predictive Biomarkers Response Sunitinib Treatment Poorly-differentiated NEURO-Endocrine Tumors</brief_title>
	<detailed_description>Neuroendocrine tumor ( NET ) rare malignancy ( 1-2 % digestive cancer ) ; , recent year , slow steady increase incidence . Despite joint effort several research group , lead new WHO classification ( 2002 ) , natural history disease remain heterogene resistance conventional cytotoxic treatment remain common denominator tumor . Indeed , prognosis patient metastatic disease remain poor despite numerous treatment ( include : IFN , DTIC , 5-FU , doxorubicin , somatostatin analogue , etc. ) . None show benefit term survival . The main therapeutic objective still get palliative effect symptom / limit month tumor progression . There many publication show angiogenesis one major mechanism tumor progression TNE . But multiple signaling pathway involve , existence alternative route relationship apoptosis inducing molecule remain unknown . Sunitinib new molecule family tyrosine kinase inhibitor target multiple receptor VEGFR , KIT , PDGF-R , FLT3 RET . Since 2006 year , Sunitinib approve treat advanced kidney cancer also call advanced renal cell carcinoma ( typically chemoresistant disease active treatment available ) . Many retrospective study patient show TNE overexpress one target sunitinib . In Phase I trial , antitumor activity identify neuroendocrine tumor . In phase II trial include 100 patient well-differentiated TNE carcinoid , sunitinib associate response rate 10 % , 82 % clinical benefit form tumor stability . Currently , international randomise phase III trial initiate well differentiate form , study underway poorly-differentiated TNE . All suggest sunitinib could represent important therapeutic option moderate , poorly differentiate inoperable TNE need explore pathology identify predictive biomarkers response .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Neuroendocrine Tumors</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Endocrine Gland Neoplasms</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<mesh_term>Angiogenesis Modulating Agents</mesh_term>
	<criteria>Digestive NET histopathologically proven , poorlydifferentiated Inoperable/advanced NET ( Tumor relapse inoperable metastatic surgical indication ) . Tumor sample make available analysis ( diagnostic biopsy , surgical specimen ) measurable disease define least one lesion wich measure least one dimension : equal superior 20 mm ( conventional method ) equal superior 10 mm ( spiral scan within 28 day begin treatment ) Performance status WHO ≤ 2 . Adequate organ function : hematology ( absolute neutrophil count equal superior 1,5 x 10*9/l , platelet equal superior 100 x 10*9/l ) , clearance creatinine equal superior 60 ml/min ) , AST/ALT ≤ 5 N , PAL ≤ 5 N , total bilirubin ≤ 2N . select woman must postmenopausal woman surgically castrate accept effective contraception duration treatment 3 month after.Women old enough procreate must negative pregnancy test within 72 hour begin treatment.They must pregnant breastfeed.the select men partner must sterile use effective contraception duration treatment 3 month . Hypersensitivity sunitinib . Contraindication sunitinib , include uncontrolled hypertension , medical history cerebrovascular accident , unstable cardiac pathology despite optimal medical therapy ( myocardial infarction within 6 month prior study drug administration , severe/unstable angina ) , active hemorrhagic syndrome concomitant treatment anticoagulant . Any severe acute chronic comorbid may compromise comply study participation : uncontrolled infection , symptomatic congestive heart failure , liver disturbance , chronic renal failure , active gastroduodenal ulcer ( nonexhaustive list ) . Known brain metastasis . Diagnosis second malignancy within last 3 year , except basal cell squamous cell skin cancer , situ carcinoma cervix uteri Current treatment another clinical trial . Prior treatment investigational agent within 4 week . Prior treatment intravenous biphosphonates</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Neuroendocrine Tumors</keyword>
	<keyword>Neuroectodermal Tumors</keyword>
	<keyword>Neoplasms , Germ Cell Embryonal</keyword>
	<keyword>Neoplasms Histologic Type</keyword>
	<keyword>Neoplasms</keyword>
	<keyword>Neoplasms , Glandular Epithelial</keyword>
	<keyword>Neoplasms , Nerve Tissue</keyword>
	<keyword>Pancreatic Neoplasms</keyword>
	<keyword>Digestive System Neoplasms</keyword>
	<keyword>Neoplasms Site</keyword>
	<keyword>Endocrine Gland Neoplasms</keyword>
	<keyword>Adenoma , Islet Cell</keyword>
	<keyword>Adenocarcinoma</keyword>
	<keyword>Carcinoma</keyword>
	<keyword>Adenoma</keyword>
	<keyword>Digestive System Diseases</keyword>
	<keyword>Pancreatic Diseases</keyword>
	<keyword>Endocrine System Diseases</keyword>
	<keyword>Sunitinib</keyword>
	<keyword>Antineoplastic Agents</keyword>
	<keyword>Therapeutic Uses</keyword>
	<keyword>Pharmacologic Actions</keyword>
	<keyword>Angiogenesis Inhibitors</keyword>
	<keyword>Angiogenesis Modulating Agents</keyword>
	<keyword>Growth Substances</keyword>
	<keyword>Physiological Effects Drugs</keyword>
	<keyword>Growth Inhibitors</keyword>
</DOC>